INSIGHTS ON DRUG DEVELOPMENT
-
![GettyImages-1309780330-HPLC-lab-scientist-chromatography]( "Get Smoother Separations, Faster: Troubleshoot Method Development")
Get Smoother Separations, Faster: Troubleshoot Method DevelopmentStrong chromatography requires more than separation. Fine-tuning pH, columns, and system volume prevents poor peak shape, while modeling tools streamline optimization for reproducible results.
-
![Matthew Schiesher]( "Ask Us Anything: Matthew Schiesher On Validation During Tech Transfer")
Ask Us Anything: Matthew Schiesher On Validation During Tech TransferMatthew Schiesher, Head of R&D at Cambrex Charles City, on validating processes under the clock — and how running multiple sites in parallel shortens the path to launch when patients are waiting.
-
![GettyImages-2190246741 lab]( "How To Capture Growth In The Expanding Metabolic Drug Market")
How To Capture Growth In The Expanding Metabolic Drug MarketDriven by GLP-1 success and rising obesity rates, R&D investment in metabolic disease therapies now rivals oncology, demanding rapid development to overcome market challenges.
-
![doctor holding vial of medicine-GettyImages-1287223643]( "A Patented Process For Intermediates Useful For Upadacitinib")
A Patented Process For Intermediates Useful For UpadacitinibDiscover how innovative and safer synthetic strategies can streamline the manufacture of Upadacitinib while addressing the complexity and safety challenges inherent in its key intermediates.
-
Analytical Method Development For Paediatric Oral Dose Products9/9/2026
This article explores the key formulation and analytical challenges that pharmaceutical companies face when creating safe, effective, and age-appropriate treatments for paediatric populations.
-
Assessing The Success Of CRISPR Gene Therapies Using ddPCR Technology3/4/2026
Achieve high-fidelity results in gene therapy research. Discover how absolute quantification overcomes traditional limitations to provide the precision needed for validating CRISPR edits.
-
The Innovation Of Testing Conjugated ADC Molecules9/2/2026
Explore how evolving ADCs are reshaping testing strategies, from potency and binding to purity, as well as what is required to evaluate both traditional cytotoxic payloads and emerging modalities.
-
Unlock The Power Of Biophysical Tools In Biotherapeutic Development7/15/2025
Unlock innovation in biotherapeutics with expert insights into DSC and molecular stability. Learn how biophysical techniques can optimize formulations and enhance nucleic acid stability.
-
Assessment Of Compound Toxicity Effects With High-Content Imaging3/17/2025
3D cellular models and bioprinting enhance drug safety predictions and offer precise spatial control. Explore an automated method for generating liver models to improve reproducibility and reliability in toxicity testing.
DRUG DEVELOPMENT SOLUTIONS
-
![ImageXpress Pico]( "Automated Cell Imaging System")
Integrate an automated cell imaging system with high-resolution imaging and robust analytics into your processes to streamline workflows for fluorescence and brightfield assays.
-
![adare]( "A Technology-Driven CDMO Delivering Integrated End-To-End Services")
Explore this interactive PDF with information about technologies & end-to-end integrated CDMO services provided by Adare Pharma Solutions.
-
![AKTA readyflux single-use tangential flow filtration systems]( "Automated, Single-Use Systems For TFF At Multiple Scales")
Platform of automated, single-use systems for tangential flow filtration at multiple scales.
-
![Thermo Fisher]( "Single-Use Chromatography System For Advanced Downstream Bioprocessing")
CDMOs, CMOs, and those working on pilot to scale-up operations can benefit from this single-use solution for chromatographic purification that offers easy integration and versatility in scale.
-
![Scientist Using Tablet In Lab GettyImages-1354172577]( "De-Risking Drug Development With PBPK Modeling")
Early identification of potential absorption risks is critical for rapid and efficient drug development. Lonza's PBPK modeling services are designed to de-risk your drug development program.
